Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (7 quarters reported)
$233M in Q4 2024 → $791M now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Viking Therapeutics Inc Call | 6.0% | Added 85% | 1,220,800 | $47.6M |
| Abivax Sa Call | 5.9% | Added 249% | 349,200 | $46.5M |
| Bristol-myers Squibb Co Call | 4.4% | New | 600,000 | $34.6M |
| Abivax Sa Put | 4.3% | Added 152% | 252,400 | $33.6M |
| UT United Therapeutics Corp Del | 3.6% | Added 94% | 52,989 | $28.7M |
| Revolution Medicines Inc | 3.3% | Added 72% | 139,218 | $26.1M |
| Abivax Sa | 2.7% | Added 115% | 163,644 | $21.6M |
| Cogent Biosciences Inc | 2.4% | Added 53% | 493,664 | $19.1M |
| Bristol-myers Squibb Co Put | 2.4% | New | 330,600 | $19M |
| Bridgebio Pharma Inc | 2.4% | Unchanged | 250,000 | $18.6M |
| Corcept Therapeutics Inc Call | 2.3% | Added 30% | 206,300 | $17.9M |
| Biomarin Pharmaceutical Inc | 2.3% | Added 111% | 312,846 | $17.9M |
| Viking Therapeutics Inc | 2.2% | Trimmed 16% | 441,808 | $17.2M |
| Kymera Therapeutics Inc Call | 2.2% | New | 149,700 | $17.2M |
| Novartis Ag Put | 2.0% | New | 100,000 | $15.7M |
| UN Uniqure Nv Put | 1.7% | Unchanged | 299,000 | $13.8M |
| Viking Therapeutics Inc Put | 1.7% | New | 350,500 | $13.7M |
| Biogen Inc Call | 1.6% | New | 60,000 | $13M |
| Capricor Therapeutics Inc Put | 1.6% | Trimmed 14% | 534,400 | $12.9M |
| Summit Therapeutics Inc Call | 1.6% | New | 860,200 | $12.5M |
| EL Eli Lilly & Co Put | 1.5% | New | 10,000 | $12M |
| Incyte Corp Put | 1.5% | Unchanged | 105,400 | $11.9M |
| Edgewise Therapeutics Inc | 1.4% | New | 272,214 | $11.1M |
| UN Uniqure Nv Call | 1.4% | Trimmed 5.8% | 235,400 | $10.8M |
| Biontech Se Call | 1.2% | New | 100,000 | $9.31M |
| Kodiak Sciences Inc | 1.1% | Added 13% | 218,117 | $8.5M |
| IH Immunocore Hldgs PLC | 1.0% | Added 32% | 254,863 | $8.09M |
| Capricor Therapeutics Inc Call | 1.0% | Unchanged | 329,300 | $7.93M |
| Novartis Ag Call | 1.0% | New | 50,000 | $7.84M |
| Replimune Group Inc Call | 1.0% | Added 239% | 696,300 | $7.71M |
| Kodiak Sciences Inc Call | 1.0% | Added 98250% | 196,700 | $7.66M |
| 4M 4d Molecular Therapeutics In | 1.0% | New | 571,107 | $7.6M |
| Moderna Inc Put | 0.9% | Trimmed 37% | 100,000 | $7M |
| Hims & Hers Health Inc Call | 0.9% | New | 200,000 | $6.93M |
| Arcus Biosciences Inc | 0.9% | Trimmed 6.0% | 223,810 | $6.9M |
| Hims & Hers Health Inc Put | 0.8% | New | 193,700 | $6.72M |
| CP Corbus Pharmaceuticals Hldgs Call | 0.8% | Added 450% | 633,800 | $5.95M |
| SL Sellas Life Sciences Group I Call | 0.7% | Added 33% | 400,000 | $5.9M |
| Kodiak Sciences Inc Put | 0.7% | Trimmed 41% | 146,900 | $5.72M |
| Alumis Inc Call | 0.7% | Added 100% | 200,000 | $5.63M |
| Royalty Pharma PLC Call | 0.7% | New | 100,000 | $5.61M |
| Johnson & Johnson | 0.7% | Trimmed 59% | 22,000 | $5.59M |
| Replimune Group Inc Put | 0.7% | Added 9.3% | 502,500 | $5.56M |
| Bioage Labs Inc Call | 0.6% | New | 200,100 | $4.9M |
| NA Novo-nordisk A S | 0.6% | Added 586% | 100,000 | $4.81M |
| Biohaven Ltd Call | 0.6% | Unchanged | 317,000 | $4.72M |
| Tenax Therapeutics Inc Call | 0.6% | New | 307,000 | $4.47M |
| Corvus Pharmaceuticals Inc | 0.6% | Added 20% | 294,811 | $4.4M |
| Relay Therapeutics Inc | 0.5% | New | 230,677 | $4.32M |
| Tg Therapeutics Inc Call | 0.5% | New | 75,700 | $4.16M |
| Monte Rosa Therapeutics Inc Call | 0.5% | New | 170,100 | $4.12M |
| Arcus Biosciences Inc Call | 0.5% | New | 124,000 | $3.82M |
| Unicycive Therapeutics Inc Call | 0.5% | New | 792,600 | $3.72M |
| Zymeworks Inc | 0.5% | Unchanged | 142,132 | $3.72M |
| Amgen Inc Call | 0.5% | New | 10,000 | $3.62M |
| Bioage Labs Inc | 0.5% | Added 144% | 146,334 | $3.59M |
| Taysha Gene Therapies Inc | 0.4% | New | 522,619 | $3.56M |
| Intellia Therapeutics Inc Call | 0.4% | Unchanged | 200,000 | $3.38M |
| CT Celldex Therapeutics Inc New Put | 0.4% | New | 86,000 | $3.2M |
| Vaxcyte Inc Call | 0.4% | Unchanged | 53,100 | $3.09M |
Showing top 60 of 149 positions.
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 6 quarters.
quarter ended June 30, 2026 · filed August 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Vertex Pharmaceuticals Inc | Exited | −93,100 | −$41.6M | — |
| Bristol-myers Squibb Co | New | +600,000 | +$34.6M | 4.4% |
| Abivax Sa | Added | +249,200 | +$33.2M | 5.9% |
| Liquidia Corporation | Exited | −662,100 | −$25M | — |
| UT United Therapeutics Corp Del | Exited | −40,200 | −$23.8M | — |
| Viking Therapeutics Inc | Added | +561,600 | +$21.9M | 6.0% |
| Abivax Sa | Added | +152,400 | +$20.3M | 4.3% |
| Bristol-myers Squibb Co | New | +330,600 | +$19M | 2.4% |
| Apogee Therapeutics Inc | Exited | −222,500 | −$18.7M | — |
| Kymera Therapeutics Inc | New | +149,700 | +$17.2M | 2.2% |
Showing the 10 largest of 190 changes.
quarter ended March 31, 2026 · filed May 15, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| SS SPDR Series Trust | Exited | −250,000 | −$30.5M | — |
| PP Praxis Precision Medicines I | Exited | −100,600 | −$29.7M | — |
| Liquidia Corporation | New | +662,100 | +$25M | 4.3% |
| UT United Therapeutics Corp Del | New | +40,200 | +$23.8M | 4.1% |
| Avidity Biosciences Inc | Exited | −328,000 | −$23.7M | — |
| Bridgebio Pharma Inc | New | +250,000 | +$18.6M | 3.2% |
| IQ Invesco Qqq Tr | Exited | −30,000 | −$18.4M | — |
| Jazz Pharmaceuticals PLC | Exited | −105,300 | −$17.9M | — |
| Bridgebio Pharma Inc | Exited | −200,000 | −$15.3M | — |
| Structure Therapeutics Inc | Exited | −191,700 | −$13.3M | — |
Showing the 10 largest of 220 changes.
quarter ended December 31, 2025 · filed February 17, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Vertex Pharmaceuticals Inc | New | +88,300 | +$40M | 6.9% |
| SS SPDR Series Trust | New | +250,000 | +$30.5M | 5.3% |
| IQ Invesco Qqq Tr | New | +30,000 | +$18.4M | 3.2% |
| Regeneron Pharmaceuticals | Trimmed | −19,860 | −$15.3M | 1.4% |
| Bridgebio Pharma Inc | New | +200,000 | +$15.3M | 2.6% |
| Johnson & Johnson | New | +66,444 | +$13.8M | 2.4% |
| Structure Therapeutics Inc | New | +191,700 | +$13.3M | 2.3% |
| SS SPDR S&P 500 ETF Tr | Exited | −20,000 | −$13.3M | — |
| Viking Therapeutics Inc | New | +316,700 | +$11.1M | 1.9% |
| Johnson & Johnson | New | +50,000 | +$10.3M | 1.8% |
Showing the 10 largest of 200 changes.
quarter ended September 30, 2025 · filed November 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| UN Uniqure Nv | New | +300,000 | +$17.5M | 4.5% |
| Amgen Inc | Exited | −62,100 | −$17.3M | — |
| Amgen Inc | Exited | −52,100 | −$14.5M | — |
| Regeneron Pharmaceuticals | Added | +24,553 | +$13.8M | 4.3% |
| SS SPDR S&P 500 ETF Tr | New | +20,000 | +$13.3M | 3.4% |
| EL Eli Lilly & Co | Exited | −14,816 | −$11.5M | — |
| Tg Therapeutics Inc | Trimmed | −310,700 | −$11.2M | 0.6% |
| Jazz Pharmaceuticals PLC | Trimmed | −81,333 | −$10.7M | 0.8% |
| Viking Therapeutics Inc | New | +405,100 | +$10.6M | 2.7% |
| Avidity Biosciences Inc | New | +200,100 | +$8.72M | 2.2% |
Showing the 10 largest of 152 changes.
quarter ended June 30, 2025 · filed August 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Amgen Inc | Exited | −103,300 | −$32.2M | — |
| Pfizer Inc | Trimmed | −700,000 | −$17M | 1.5% |
| Soleno Therapeutics Inc | Added | +191,150 | +$16M | 7.3% |
| Soleno Therapeutics Inc | Exited | −219,400 | −$15.7M | — |
| Soleno Therapeutics Inc | Exited | −217,000 | −$15.5M | — |
| Amgen Inc | New | +52,100 | +$14.5M | 4.4% |
| Regeneron Pharmaceuticals | Trimmed | −24,221 | −$12.7M | 0.9% |
| Regeneron Pharmaceuticals | Exited | −20,000 | −$12.7M | — |
| NA Novo-nordisk A S | Exited | −124,600 | −$8.65M | — |
| SS SPDR Series Trust | New | +100,000 | +$8.29M | 2.5% |
Showing the 10 largest of 119 changes.
quarter ended March 31, 2025 · filed May 15, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Amgen Inc | New | +103,300 | +$32.2M | 8.4% |
| Vertex Pharmaceuticals Inc | Exited | −57,400 | −$23.1M | — |
| Pfizer Inc | New | +900,000 | +$22.8M | 6.0% |
| Regeneron Pharmaceuticals | New | +29,828 | +$18.9M | 4.9% |
| SS SPDR Ser Tr | Exited | −200,000 | −$18M | — |
| Corcept Therapeutics Inc | New | +150,200 | +$17.2M | 4.5% |
| EL Eli Lilly & Co | New | +20,700 | +$17.1M | 4.5% |
| Amgen Inc | New | +52,100 | +$16.2M | 4.2% |
| EL Eli Lilly & Co | New | +19,302 | +$15.9M | 4.2% |
| Regeneron Pharmaceuticals | New | +20,000 | +$12.7M | 3.3% |
Showing the 10 largest of 162 changes.
Loading...
